ESK-001 is a small molecule commercialized by Alumis, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 9 clinical trials, of which ...
AbbVie (NYSE: ABBV) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...
No significant differences in clinical outcomes were observed between ABP 654 and ustekinumab reference product in patients with plaque psoriasis, including among patients who transitioned from ...